{"id":26606,"date":"2024-02-05T08:53:45","date_gmt":"2024-02-05T07:53:45","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=26606"},"modified":"2024-02-05T08:54:42","modified_gmt":"2024-02-05T07:54:42","slug":"bayer-vinner-patentmal-avseende-xarelto-rivaroxaban-i-patent-och-marknadsdomstolen","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/bayer-vinner-patentmal-avseende-xarelto-rivaroxaban-i-patent-och-marknadsdomstolen\/","title":{"rendered":"Bayer vinner patentm\u00e5l avseende Xarelto\u00ae (rivaroxaban) i Patent- och marknadsdomstolen"},"content":{"rendered":"<p class=\"preamble\">Den 1 februari 2024 meddelade Patent- och marknadsdomstolen dom avseende Bayers patent som skyddar dosering en g\u00e5ng om dagen av rivaroxaban \u2013 den aktiva substansen i antikoagulantian Xarelto\u00ae.<\/p>\n<p>Under 2022 v\u00e4ckte Sandoz talan vid Patent- och marknadsdomstolen. Sandoz beg\u00e4rde att det europeiska patentet 1\u00a0845\u00a0961 skulle f\u00f6rklaras ogiltigt i Sverige. Patentet skyddar en daglig dosering av rivaroxaban, den aktiva substansen i Bayers stors\u00e4ljande l\u00e4kemedel Xarelto\u00ae, f\u00f6r behandling av tromboemboliska st\u00f6rningar. Sandoz gjorde g\u00e4llande att patentet var ogiltigt p\u00e5 grund av bristande uppfinningsh\u00f6jd. En sex dagar l\u00e5ng huvudf\u00f6rhandling h\u00f6lls\u00a0i slutet av 2023.<\/p>\n<p>Bayer f\u00f6rsvarade framg\u00e5ngsrikt patentet. Den 1 februari 2024 meddelade domstolen dom (m\u00e5l nummer PMT 16592-22). Domstolen avslog Sandoz talan och gav Bayer ers\u00e4ttning f\u00f6r r\u00e4tteg\u00e5ngskostnader. Domen kan \u00f6verklagas och pr\u00f6vningstillst\u00e5nd kr\u00e4vs.<\/p>\n<p>Xarelto\u00ae \u00e4r ett framg\u00e5ngsrikt l\u00e4kemedel som har hj\u00e4lpt miljontals m\u00e4nniskor och f\u00e5tt flera priser.<\/p>\n<p>Mannheimer Swartling f\u00f6retr\u00e4dde Bayer tillsammans med patentombud fr\u00e5n Cohausz &amp; Florack.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Den 1 februari 2024 meddelade Patent- och marknadsdomstolen dom avseende Bayers patent som skyddar dosering en g\u00e5ng om dagen av rivaroxaban \u2013 den aktiva substansen\u2026<\/p>\n","protected":false},"author":10,"featured_media":26609,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-26606","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-immaterialratt-marknadsratt-och-medieratt"],"acf":[],"lang":"sv","translations":{"sv":26606,"en":26615},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26606"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=26606"}],"version-history":[{"count":3,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26606\/revisions"}],"predecessor-version":[{"id":26614,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26606\/revisions\/26614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/26609"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=26606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=26606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=26606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}